Tag Archive for: conference attendance

Resolution Therapeutics to present EMERALD study design at the British Association for the Study of the Liver (BASL) annual meeting 2025

/in

EMERALD Chief Investigator Prof. Jonathan Fallowfield will present the poster on study design EMERALD is a multicentre Phase I/II study evaluating Resolution’s Regenerative Macrophage Therapy RTX001 in patients with end-stage liver disease taking place in the UK and Spain First patient dosed successfully, and safety cleared at Royal Infirmary of Edinburgh Edinburgh and London, UK, […]

Read more

Poolbeg to Participate in Key Conferences in March and April 2025

/in

Poolbeg to present at Master Investor Show, BioTrinity & Participate in a Panel Discussion at LSX World Congress 27 March 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that CEO, Jeremy Skillington, will be participating in the following leading industry […]

Read more

Domain Therapeutics to present and participate at major global healthcare conferences, March to June 2025

/in

Domain’s leadership will highlight advancements in its key programs in immuno-oncology and inflammation Key presentations on its first-in-class biased antagonist of PAR2 and best-in-class Treg-depleting anti-CCR8 antibody candidates Strasbourg, France – Montreal, Canada – Boston, United States, February 27, 2025: Domain Therapeutics (“Domain” or “the Company”), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for […]

Read more

Resolution Therapeutics Announces Upcoming Presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024

/in

– Oral Presentation of complete data from the three-year MATCH Phase 2 trial – Poster Presentation demonstrating preclinical proof of concept of safety and efficacy of RTX001, an autologous engineered macrophage cell therapy for end stage liver disease Edinburgh and London, UK, 1 October 2024 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company […]

Read more

IO Biotech Announces Participation in Upcoming Investor Conferences

/in

NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced its participation in the upcoming investor conferences: Event: Jefferies London Healthcare Conference Location: London One-on-one meetings: Wednesday, November 15, 2023 Participants: Mai-Britt Zocca, PhD, President and […]

Read more